Source - LSE Regulatory
RNS Number : 8653Q
Diurnal Group PLC
30 June 2022
 

30 June 2022

 

Diurnal Group plc

("Diurnal" or the "Company")

 

Block Listing Six Monthly Return

 

 

Pursuant to AIM Rule 29 and Schedule 6 of the AIM Rules for Companies, Diurnal Group plc makes the following update on its block listing:

 

Name of applicant:

Diurnal Group plc

Name of scheme:

Long Term Incentive Plan

Period of return:

From:

17 December 2021

To:

30 June 2022

Balance of unallotted securities under scheme(s) from previous return:

5,775,000

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

665,732

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

5,109,268

 

Name of contact:

Mike Scott

Telephone number of contact:

+44 (0)20 3727 1000

 

 

For further information, please visit www.diurnal.co.uk or contact:



Diurnal Group plc

+44 (0)20 3727 1000

Richard Bungay, Interim Chief Executive Officer




Panmure Gordon (UK) Limited (Nominated Adviser and Joint Corporate Broker)

+44 (0)20 7886 2500

Corporate Finance: Freddy Crossley, Emma Earl


Corporate Broking: Rupert Dearden

 


Stifel Nicolaus Europe Limited (Joint Corporate Broker)

+44 (0) 20 7710 7600


Healthcare Investment Banking: Nicholas Moore, Samira Essebiyea, William Palmer-Brown



Corporate Broking: Nick Adams, Nick Harland





FTI Consulting (Media and Investor Relations)

+44 (0)20 3727 1000

Simon Conway


Victoria Foster Mitchell


Alex Davis




Vane Percy & Roberts (Medical Communications)

+44 (0) 173 782 1890

Simon Vane Percy


 

Notes to Editors

 

About Diurnal Group plc

Diurnal Group plc is a European, UK-headquartered, specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism and hypothyroidism. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.

 

For further information about Diurnal, please visit www.diurnal.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BLREAAKEDAPAEFA
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. AJBell logo

Related Charts